Literature DB >> 15554769

Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.

Fady Rachid1, Gilles Bertschy, Guido Bondolfi, Jean-Michel Aubry.   

Abstract

BACKGROUND: Atypical antipsychotics are widely used in clinical practice for several psychiatric disorders. Between 1994 and 1999, 26 cases of manic and hypomanic syndromes were reported with olanzapine and risperidone and were described in a previous review article.
METHOD: An updated MEDLINE search (1999-2003) using the terms atypical antipsychotics, amisulpride, aripiprazole, clozapine, flupenthixol, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine, hypomania, and mania showed that 34 new cases of induced hypomanic or manic syndromes have been published, not only with olanzapine (N = 5) and risperidone (N = 6), but also with quetiapine (N = 5) and ziprasidone (N = 11) treatment. Six cases have been reported with flupenthixol and 1 with amisulpride, two antipsychotics considered as "partial" atypicals.
RESULTS: A critical analysis of these case reports revealed that the effects on mood were insufficiently documented in some of the reports but that for 20 of them, evidence is highly suggestive of a causative role of atypical antipsychotics in the induction of manic/hypomanic symptomatology.
CONCLUSION: This updated review continues and extends the results of the initial review and suggests that atypical antipsychotics have some intriguing effects on mood. Such effects have never been reported with conventional antipsychotics. The mechanisms involved in this phenomenon of mood switch remain to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554769     DOI: 10.4088/jcp.v65n1116

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Transition to mania during treatment of bipolar depression.

Authors:  Roy H Perlis; Michael J Ostacher; Joseph F Goldberg; David J Miklowitz; Edward Friedman; Joseph Calabrese; Michael E Thase; Gary S Sachs
Journal:  Neuropsychopharmacology       Date:  2010-09-08       Impact factor: 7.853

Review 2.  A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder.

Authors:  Hiroyoshi Takeuchi; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-06-05       Impact factor: 4.530

Review 3.  Atypical antipsychotics for the treatment of bipolar disorder: more shadows than lights.

Authors:  Salvatore Gentile
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Mania in the medically ill.

Authors:  Monica Arora; Joan Daughton
Journal:  Curr Psychiatry Rep       Date:  2007-06       Impact factor: 5.285

5.  Repeated activation of mania by atypical antipsychotics in a patient.

Authors:  Ashwati Raghunath
Journal:  BMJ Case Rep       Date:  2012-11-27

Review 6.  Atypical antipsychotics for people with both schizophrenia and depression.

Authors:  V A Furtado; V Srihari
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

7.  Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations: A Case Series of Bipolar Type 2 Patients.

Authors:  C Rovera; C M Esposito; V Ciappolino; D Cattaneo; S Baldelli; E Clementi; A C Altamura; M Buoli
Journal:  Drug Saf Case Rep       Date:  2017-10-23

8.  The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder.

Authors:  Emanuela Mundo; Elisabetta Cattaneo; Silvia Zanoni; A Carlo Altamura
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

9.  Medical treatment and weight gain.

Authors:  Eileen McGinn
Journal:  Prev Chronic Dis       Date:  2007-06-15       Impact factor: 2.830

10.  Blonanserin-induced Mood Alteration in Schizophrenia and Schizoaffective Disorder: Two Cases.

Authors:  Aran Min; Daeho Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-12-24       Impact factor: 2.582

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.